Outcome Data from the CDC Perinatal Hepatitis B Prevention Program — 2021 Birth Cohort

Outcome data on infants born to persons with hepatitis B virus (HBV) infection are collected, analyzed, and reported by the CDC Perinatal Hepatitis B Prevention Program (PHBPP),1 which funds 64 jurisdictions to identify pregnant persons with HBV infection and to manage the healthcare of their infants to improve receipt of post-exposure prophylaxis (PEP) (hepatitis B vaccine birth dose and hepatitis B immune globulin), hepatitis B vaccine series completion, and post-vaccination serologic testing.

Participating jurisdictions are the 50 United States, District of Columbia, five cities (Chicago, Houston, New York City, Philadelphia, and San Antonio), five US territories (American Samoa, Guam, N. Mariana Islands, Puerto Rico, and US Virgin Islands), and three freely associated states (Federated States of Micronesia, Republic of the Marshall Islands, and Republic of Palau). Data in this report are from the reporting period for the 2021 birth cohort, followed from January 1, 2021–December 31, 2022, and only include infants whose care was managed by the program.

Follow-up time for infants varies in length depending on their date of birth. Because of differences in the states and jurisdictions participating, not all cases among infants identified as hepatitis B surface antigen (HBsAg) positive within the PHBPP are reported to the CDC National Notifiable Diseases Surveillance System (NNDSS).